Platelet aggregation inhibitors work in different places of the clotting cascade and prevent platelet adhesion, therefore no clot formation.
Aspirin, the most commonly used antiplatelet drug changes the balance between prostacyclin (which inhibits platelet aggregation) and thromboxane (that promotes aggregation). It irreversibly inhibits the enzyme cyclo-oxygenase, which leads to reduction in thromboxane synthesis in platelets and prostacyclin in vascular endothelial cells. The vascular endothelium recovers and can synthesize more prostacyclin but thromboxane synthesis only recovers after new platelets are formed.
Platelet aggregation inhibitors are used acutely in myocardial infarction, atrial fibrillation, following coronary bypass, angioplasty and stenting. It is also used as prophylaxis to prevent myocardial infarction and stroke.
Subscribe to receive email notifications whenever new articles are published.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex® (updated Sep 1st, 2017), Cerner Multum™ (updated Sep 4th, 2017), Wolters Kluwer™ (updated Sep 6th, 2017) and others. To view content sources and attributions, please refer to our editorial policy.